Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 6/20 | 0.38 |
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | HTR2A | P28223 | 5/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 2/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24738259 | 1.00 | HRH1 (0.38) | HRH1DRD2HTR2AHRH4HRH3 | |
| SCHEMBL29302918 | 0.85 | HRH4 (0.35) | HRH1DRD2HRH4HRH3DRD4 | |
| SCHEMBL29879251 | 0.83 | HRH4 (0.32) | HRH4KLKB1 | |
| SCHEMBL24737991 | 0.83 | HRH4 (0.32) | HRH4KLKB1 | |
| SCHEMBL24738494 | 0.81 | ADRA2B (0.37) | HTR2AHRH4HRH3IGF1RKLKB1 | |
| SCHEMBL29879202 | 0.81 | ADRA2B (0.37) | HTR2AHRH4HRH3IGF1RKLKB1 | |
| SCHEMBL24737667 | 0.80 | HRH4 (0.38) | DRD2HRH4HRH3IGF1RDRD4 | |
| SCHEMBL30997777 | 0.79 | ACHE (0.39) | HRH4HRH3IGF1R | |
| SCHEMBL30997764 | 0.79 | HRH4 (0.36) | DRD2HRH4HRH3CCNT1CDK9 | |
| SCHEMBL24737418 | 0.79 | ACHE (0.39) | HRH4HRH3IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | HRH1 2262/4885DRD2 4414/4885HTR2A 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.